Tuesday, July 23, 2019

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Remains Ahead of the Pack with Innovative Delivery Technology


Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the developer of the drug-delivery platform DehydraTECH(TM). The company’s innovative technology promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. An article discussing the company reads, “One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech. . . . Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319% higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://ibn.fm/tKbuo). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.”

To view the full article, visit http://ibn.fm/0yWPp

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive, patented-delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: